Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis

Christos Thomadakis, Ilias Gountas*, Erika Duffell, Konstantinos Gountas, Benjamin Bluemel, Thomas Seyler, Filippo Maria Pericoli, Irene Kászoni-Rückerl, Ziad El-Khatib, Martin Busch, Irene Schmutterer, Thomas Vanwolleghem, Sofieke Klamer, Els Plettinckx, Laure Mortgat, Dominique Van Beckhoven, Tonka Varleva, Mirjana Lana Kosanovic Licina, Tatjana Nemeth Blazic, Diana NonkovićFanitsa Theophanous, Vratislav Nemecek, Marek Maly, Peer Brehm Christensen, Susan Cowan, Kristi Rüütel, Henrikki Brummer-Korvenkontio, Cécile Brouard, Gyde Steffen, Amrei Krings, Sandra Dudareva, Ruth Zimmermann, Georgia Nikolopoulou, Zsuzsanna Molnár, Emese Kozma, Magnús Gottfredsson, Niamh Murphy, Loreta A. Kondili, Maria Elena Tosti, Anna Rita Ciccaglione, Barbara Suligoi, Raina Nikiforova, Renate Putnina, Ligita Jancoriene, Carole Seguin-Devaux, Tanya Melillo, Anders Boyd, Marc van der Valk, Eline Op de Coul, Robert Whittaker, Hilde Kløvstad, Małgorzata Stępień, Magdalena Rosińska, Cristina Valente, Rui Tato Marinho, Odette Popovici, Mária Avdičová, Jana Kerlik, Irena Klavs, Mojca Maticic, Asuncion Diaz, Julia del Amo, Josefine Lundberg Ederth, Maria Axelsson, Georgios Nikolopoulos*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Epidemiological data are crucial to monitoring progress towards the 2030 Hepatitis C Virus (HCV) elimination targets. Our aim was to estimate the prevalence of chronic HCV infection (cHCV) in the European Union (EU)/European Economic Area (EEA) countries in 2019. Methods: Multi-parameter evidence synthesis (MPES) was used to produce national estimates of cHCV defined as: π = πrecρrec + πexρex + πnonρnon; πrec, πex, and πnon represent cHCV prevalence among recent people who inject drugs (PWID), ex-PWID, and non-PWID, respectively, while ρrec, ρex, and ρnon represent the proportions of these groups in the population. Information sources included the European Centre for Disease Prevention and Control (ECDC) national operational contact points (NCPs) and prevalence database, the European Monitoring Centre for Drugs and Drug Addiction databases, and the published literature. Findings: The cHCV prevalence in 29 of 30 EU/EEA countries in 2019 was 0.50% [95% Credible Interval (CrI): 0.46%, 0.55%]. The highest cHCV prevalence was observed in the eastern EU/EEA (0.88%; 95% CrI: 0.81%, 0.94%). At least 35.76% (95% CrI: 33.07%, 38.60%) of the overall cHCV prevalence in EU/EEA countries was associated with injecting drugs. Interpretation: Using MPES and collaborating with ECDC NCPs, we estimated the prevalence of cHCV in the EU/EEA to be low. Some areas experience higher cHCV prevalence while a third of prevalent cHCV infections was attributed to PWID. Further efforts are needed to scale up prevention measures and the diagnosis and treatment of infected individuals, especially in the east of the EU/EEA and among PWID. Funding: ECDC.

Original languageEnglish
Article number100792
JournalThe Lancet Regional Health - Europe
Volume36
DOIs
Publication statusPublished - Jan 2024

Keywords

  • Chronic hepatitis
  • Elimination
  • Europe
  • HCV
  • Hepatitis C
  • Prevalence

Fingerprint

Dive into the research topics of 'Prevalence of chronic HCV infection in EU/EEA countries in 2019 using multiparameter evidence synthesis'. Together they form a unique fingerprint.

Cite this